I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| naive B cell | 14 studies | 21% ± 6% | |
| B cell | 9 studies | 23% ± 4% | |
| T follicular helper cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| naive B cell | 14 studies | 21% ± 6% | |
| B cell | 9 studies | 23% ± 4% | |
| T follicular helper cell | 3 studies | 21% ± 4% |
Insufficient scRNA-seq data for expression of BTLA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 98% | 53.22 | 566 / 578 | 48% | 1.27 | 555 / 1155 |
| breast | 76% | 18.34 | 350 / 459 | 38% | 1.29 | 425 / 1118 |
| thymus | 79% | 50.13 | 517 / 653 | 30% | 1.06 | 184 / 605 |
| skin | 62% | 11.84 | 1116 / 1809 | 39% | 1.85 | 185 / 472 |
| spleen | 100% | 707.09 | 241 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 1179.83 | 912 / 929 | 0% | 0 | 0 / 0 |
| kidney | 72% | 25.70 | 64 / 89 | 25% | 0.58 | 228 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 21.58 | 27 / 29 |
| stomach | 69% | 20.67 | 248 / 359 | 24% | 0.58 | 68 / 286 |
| adipose | 86% | 24.40 | 1035 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 84% | 25.14 | 1118 / 1335 | 0% | 0 | 0 / 0 |
| intestine | 67% | 118.74 | 646 / 966 | 17% | 0.54 | 87 / 527 |
| prostate | 66% | 16.18 | 161 / 245 | 12% | 0.28 | 62 / 502 |
| uterus | 54% | 7.77 | 92 / 170 | 20% | 0.39 | 91 / 459 |
| bladder | 52% | 23.19 | 11 / 21 | 18% | 0.39 | 93 / 504 |
| liver | 58% | 8.10 | 130 / 226 | 8% | 0.26 | 34 / 406 |
| esophagus | 44% | 11.21 | 634 / 1445 | 20% | 0.54 | 36 / 183 |
| tonsil | 0% | 0 | 0 / 0 | 62% | 1.83 | 28 / 45 |
| ovary | 37% | 4.54 | 66 / 180 | 23% | 0.50 | 99 / 430 |
| pancreas | 20% | 2.49 | 67 / 328 | 37% | 1.52 | 65 / 178 |
| adrenal gland | 37% | 4.67 | 96 / 258 | 0% | 0.01 | 1 / 230 |
| brain | 34% | 4.49 | 909 / 2642 | 2% | 0.05 | 13 / 705 |
| heart | 21% | 3.01 | 182 / 861 | 0% | 0 | 0 / 0 |
| muscle | 9% | 1.04 | 71 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.08 | 4 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002768 | Biological process | immune response-regulating cell surface receptor signaling pathway |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | BTLA |
| Protein name | Alternative protein BTLA B- and T-lymphocyte attenuator (B- and T-lymphocyte-associated protein) (CD antigen CD272) B and T lymphocyte attenuator (cDNA FLJ75957, highly similar to Homo sapiens B and T lymphocyte associated (BTLA), mRNA) |
| Synonyms | |
| Description | FUNCTION: Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 . May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14 . In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells . . |
| Accessions | Q400G7 ENST00000383680.4 [Q7Z6A9-2] Q7Z6A9 ENST00000334529.10 [Q7Z6A9-1] L8EAT9 |
